PARIS—Sanofi SA on Thursday said it has made an all-cash offer to acquire Medivation Inc. in a deal valued at $9.3 billion, the French drugmaker's latest effort to expand its cancer-treatment business.

Sanofi said it would pay $52.50 a Medivation share, a premium of over 50% to Medivation's average share price for the two months before speculation of a takeover surfaced.

Medivation is a Nasdaq-listed company based in San Francisco with one marketed prostate cancer therapy, called Xtandi, and two additional oncology assets in clinical development.

Sanofi Chief Executive Olivier Brandicourt said the deal fit the company's strategy. "With Medivation's best-in-class offerings in prostate cancer, we believe a combination would benefit patients and, at the same time, generate value for shareholders of both companies."

Write to Nick Kostov at Nick.Kostov@wsj.com

 

(END) Dow Jones Newswires

April 28, 2016 03:05 ET (07:05 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Medivation, Inc. (MM) Charts.
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Medivation, Inc. (MM) Charts.